Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Materials

Artificial ovary uses cells to deliver hormone replacement therapy

Health benefits are achieved in rats with lower hormone doses than current estrogen-based drug treatment

by Celia Henry Arnaud
December 18, 2017 | A version of this story appeared in Volume 95, Issue 49

[+]Enlarge
Credit: Nat. Commun.
This ovarian-follicle mimic delivers cell-based hormone replacement therapy that could replace current drug therapies at lower doses and with fewer side effects.
Schematic of a three-layered ovarian construct containing granulosa and theca cells embedded in alginate layers.
Credit: Nat. Commun.
This ovarian-follicle mimic delivers cell-based hormone replacement therapy that could replace current drug therapies at lower doses and with fewer side effects.

Women whose ovaries stop functioning because of either menopause or disease can experience health effects that go beyond the loss of fertility, including osteoporosis and obesity. The standard treatment—hormone replacement with estrogen alone or in combination with progestin—can mitigate those problems. But the treatment comes with other risks, including an increased chance of breast cancer and heart disease. A team led by Emmanuel C. Opara of Wake Forest School of Medicine is developing bioengineered polymeric capsules that mimic ovarian follicles for use as a cell-based method of hormone replacement (Nat. Commun. 2017, DOI: 10.1038/s41467-017-01851-3). To make these artificial ovaries, the researchers encapsulate two types of hormone-producing ovarian cells—granulosa and theca cells—in separate layers of cross-linked alginate (a polysaccharide) with layers of poly-l-ornithine between. They tested the capsules by implanting them in rats whose ovaries had been removed and comparing the performance with rats whose ovaries had been removed and treated using hormone-containing pellets at high and low doses of estrogen with or without progestin. After 90 days, rats that received the cell-based therapy had similar body weight, fat percentage, bone mineral density, and uterine morphology as rats with intact ovaries. These positive effects were achieved with hormone levels in the blood that were lower in rats receiving the cell-based therapy than in rats receiving the hormone pellets or in rats whose ovaries were still intact.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.